Monte Rosa Therapeutics, Inc. (GLUE)
14.22
-0.09
(-0.63%)
USD |
NASDAQ |
Sep 02, 16:00
14.23
+0.01
(+0.07%)
After-Hours: 16:51
Monte Rosa Therapeutics Research and Development Expense (Annual) : 133.14M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 133.14M |
| December 31, 2024 | 113.44M |
| December 31, 2023 | 105.05M |
| December 31, 2022 | 76.50M |
| Date | Value |
|---|---|
| December 31, 2021 | 55.02M |
| December 31, 2020 | 23.47M |
| December 31, 2019 | 7.278M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Nurix Therapeutics, Inc. | 308.16M |
| Gilead Sciences, Inc. | 5.688B |
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| Capricor Therapeutics, Inc. | 83.50M |
| Cue Biopharma, Inc. | 37.43M |